Literature DB >> 1484318

Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium.

M Ramael1, G Lemmens, C Eerdekens, C Buysse, I Deblier, W Jacobs, E van Marck.   

Abstract

The presence of p53 protein in non-neoplastic pleural mesothelium (40 cases) and in human malignant mesothelioma (36 cases) was assessed immunohistochemically using the antibodies DO7, CM-1, and PAb240. In a quarter of the malignant mesotheliomas, there was nuclear immunoreactivity for p53 protein with both the DO7 and CM-1 antibodies. There were no statistically significant differences between the various mesothelioma subtypes (P > 0.05). No immunoreactivity was found with the PAb240 antibody, suggesting absence of mutant-type p53 protein. Nonneoplastic mesothelium was not immunoreactive with any of the antibodies. We conclude that there is immunoreactivity for p53 protein in some mesotheliomas. p53 protein immunoreactivity could be used to discriminate between neoplastic and reactive mesothelium.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1484318     DOI: 10.1002/path.1711680406

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  9 in total

1.  Association of p53 and WAF1 expression with apoptosis in diffuse alveolar damage.

Authors:  D Guinee; M Fleming; T Hayashi; M Woodward; J Zhang; J Walls; M Koss; V Ferrans; W Travis
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

2.  Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma.

Authors:  K Segers; H Backhovens; S K Singh; J De Voecht; M Ramael; C Van Broeckhoven; E Van Marck
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

3.  BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.

Authors:  Marta Cigognetti; Silvia Lonardi; Simona Fisogni; Piera Balzarini; Vilma Pellegrini; Andrea Tironi; Luisa Bercich; Mattia Bugatti; Giulio Rossi; Bruno Murer; Mattia Barbareschi; Silvia Giuliani; Alberto Cavazza; Gianpietro Marchetti; William Vermi; Fabio Facchetti
Journal:  Mod Pathol       Date:  2015-05-29       Impact factor: 7.842

Review 4.  Pathological and molecular biological approaches to early mesothelioma.

Authors:  Tohru Tsujimura; Ikuko Torii; Ayuko Sato; Misa Song; Kazuya Fukuoka; Seiki Hasegawa; Takashi Nakano
Journal:  Int J Clin Oncol       Date:  2012-01-12       Impact factor: 3.402

5.  Malignant mesothelioma eight years after a diagnosis of atypical mesothelial hyperplasia.

Authors:  J Scurry; M A Duggan
Journal:  J Clin Pathol       Date:  1999-07       Impact factor: 3.411

6.  Midgut Carcinoids and Solid Carcinomas of the Intestine: Differences in Endocrine Markers and p53 Mutations.

Authors:  Peder Weckstrom; Anders Hedrum; Charlie Makridis; Goran Akerstrom; Jonas Rastad; Lena Scheibenpflug; Mattias Uhlen; Claes Juhlin; Erik Wilander
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

7.  p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.

Authors:  J Creaney; B M McLaren; S Stevenson; A W Musk; N de Klerk; B W Robinson; R A Lake
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

8.  FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15.

Authors:  Ningning Li; Federica Lorenzi; Eliana Kalakouti; Makhliyo Normatova; Roya Babaei-Jadidi; Ian Tomlinson; Abdolrahman S Nateri
Journal:  Oncotarget       Date:  2015-04-20

9.  Triple-negative expression (ALDH1A1-/CD133-/mutant p53-) cases in lung adenocarcinoma had a good prognosis.

Authors:  Naoki Yamashita; Tetsuya So; Takeaki Miyata; Takashi Yoshimatsu; Ryuji Nakano; Tsunehiro Oyama; Wataru Matsunaga; Akinobu Gotoh
Journal:  Sci Rep       Date:  2022-01-27       Impact factor: 4.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.